Contingencies and commitments - Alpine Collaboration Agreement (Details) - Alpine Immune Sciences Inc. - USD ($) |
1 Months Ended | 12 Months Ended | |
|---|---|---|---|
Jun. 30, 2019 |
Dec. 31, 2022 |
Dec. 31, 2019 |
|
| Maximum | |||
| Contingencies and commitments | |||
| Potential milestone payments | $ 288,000,000 | ||
| Research and Development Expense | |||
| Contingencies and commitments | |||
| Upfront license fees | $ 2,000,000 | $ 2,000,000 | |
| Milestone payments | $ 1,000,000 | ||
| X | ||||||||||
- Definition Represents the amount of payments that the entity is required to make under the agreement, upon achievement of certain development and product milestones. No definition available.
|
| X | ||||||||||
- Definition Represents the amount of milestone payments made by the entity under the license agreement. No definition available.
|
| X | ||||||||||
- Definition Represents the amount of upfront license fees paid. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|